Stuttgart - Delayed Quote EUR

CervoMed Inc. (DP8.SG)

1.8000

-3.4500

(-65.71%)

At close: December 13 at 9:35:20 PM GMT+1

CervoMed price target lowered to $4 from $45 at Roth MKM

Roth MKM lowered the firm’s price target on CervoMed (CRVO) to $4 from $45 and keeps a Buy rating on the shares. The company has reported negative top-line results from the Phase 2b RewinD-LB – dementia with Lewy bodies – study of neflamapimod in pure DLB patients, raising questions about the program’s viability, the analyst tells investors in a research note. A potential reason for failure could be the drug’s inability to achieve the desired plasma concentration – a proxy for efficacy – and Cer

TipRanks 3 days ago

CRVO
CervoMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Dec. 12, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO) (the “Company”), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that it has granted equity awards as a material inducement to the employment of two new employees. On December 6, 2024, the Company granted options to purchase an aggregate of 14,753 shares of common stock to two new employees. Each option has an exercise price of $11.91, the closing price of the Co

GlobeNewswire 3 days ago

CRVO
CervoMed announces RewinD-LB Phase 2b did not meet primary endpoint

CervoMed (CRVO) announced topline data from the RewinD-LB Phase 2b clinical trial evaluating neflamapimod for the treatment of patients with dementia with Lewy bodies. DLB. The trial did not meet statistical significance thresholds for its primary endpoint of change in the Clinical Dementia Rating Sum of Boxes, CDR-SB, or any of its key secondary endpoints – change from baseline in Timed Up and Go, TUG, test, change from baseline in a Neuropsychological Test Battery, NTD, and the Clinician’s Glo

TipRanks 4 days ago

CRVO
CervoMed Announces Topline Data from RewinD-LB Phase 2b Clinical Trial in Patients with Dementia with Lewy Bodies

—Neflamapimod did not demonstrate statistically significant effects versus placebo on primary and secondary endpoints at 16 weeks— —Favorable safety and tolerability results with no new safety signal identified— —Target plasma drug concentrations not achieved during 16-week double-blind phase of the trial— —Trial participants continue to receive neflamapimod during open-label extension— BOSTON, Dec. 10, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO) (“CervoMed” or the “Company”), a clinic

GlobeNewswire 5 days ago

CRVO
CervoMed Announces Orphan Drug Designation Granted to Neflamapimod by U.S. Food and Drug Administration for the Treatment of Frontotemporal Dementia

Designation underscores significant unmet need in frontotemporal dementia and the potential role of neflamapimod in multiple neurologic disorders On track to report topline data from the RewinD-LB Phase 2b clinical trial in early-stage dementia with Lewy bodies (DLB) in December 2024 BOSTON, Nov. 27, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage company focused on developing treatments for age-related neurologic disorders, today announced that its oral investigational d

GlobeNewswire 18 days ago

CRVO
CervoMed Announces Key Senior Leadership Appointments

New hires in key scientific and regulatory roles to advance continued development of neflamapimodBOSTON, Nov. 13, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today reported two senior leadership appointments to advance continued development of neflamapimod. Claudia Ordonez, MD, joined CervoMed as Senior Vice President, Medical Science in October 2024. Dr. Ordonez was previously Chief Medica

GlobeNewswire last month

CRVO
CervoMed Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

- Reported last patient, last visit in its RewinD-LB Phase 2b clinical trial evaluating neflamapimod in patients with early-stage dementia with Lewy bodies (DLB) in October 2024; topline data expected in December 2024 – - Hosted a virtual key opinion leader event in July 2024 highlighting neflamapimod’s potential for patients with early-stage DLB – BOSTON, Nov. 12, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neu

GlobeNewswire last month

CRVO
CervoMed Awarded the Prix Galien USA 2024 Prize for Best Startup

The Prix Galien USA Best Startup category recognizes outstanding innovation by therapeutics-focused life science companies that have not yet received their first product approval The award to CervoMed recognizes the advances made by the company towards developing the first treatment for Dementia with Lewy bodies (DLB) BOSTON, Nov. 08, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage company focused on developing treatments for age-related neurologic disorders, announced to

GlobeNewswire last month

CRVO
CervoMed to Participate in Upcoming Investor Conferences

BOSTON, Nov. 07, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that the Company’s Management will participate in the following investor conferences during the month of November: Sidoti Virtual Micro Cap ConferenceFormat: Corporate presentation Date: Thursday, November 14, 2024Time: 2:30 PM ETWebcast Link: click here Stifel 2024 Healthcare ConferenceFormat: Corporate presentati

GlobeNewswire last month

CRVO
CervoMed Announces Key Takeaways from Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)

Data from the AscenD-LB Phase 2a trial in DLB confirm recent scientific literature indicating that plasma glial fibrillary acid protein (GFAP) is a robust measure of neurodegenerative disease activity in DLB Neflamapimod treatment previously led to significant reduction in plasma GFAP levels (p=0.015 versus placebo) and these reductions were associated with an improvement in clinical outcomes The RewinD-LB Phase 2b clinical study successfully enrolled a DLB patient population that is optimized t

GlobeNewswire last month

CRVO
CervoMed to Deliver Oral Presentation at the 8th International Lewy Body Dementia Conference

Topline data from the RewinD-LB Phase 2b study on track for December 2024 Detailed safety and efficacy data from RewinD-LB Phase 2b study to be featured in an oral presentation at the ILBDC conference in January 2025 BOSTON, Oct. 29, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage company focused on developing treatments for age-related neurologic disorders, today announced that it will deliver an oral presentation providing detailed safety and efficacy results from its c

GlobeNewswire last month

CRVO
CervoMed Announces Last Patient Last Visit in Phase 2b RewinD-LB Trial of Neflamapimod for the Treatment of Early-Stage Dementia with Lewy Bodies (DLB)

• On track to report topline data from the Phase 2b trial in December 2024 • Neflamapimod has the potential to restore function and improve cognitive and motor functions in DLB patients • 96% of patients enrolled in RewinD-LB completed the 16-week portion of the study, of which 98% continued into the open label extension BOSTON, Oct. 15, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage company focused on developing treatments for age-related neurologic disorders, today ann

GlobeNewswire last month

CRVO
CervoMed Ends $20 Million Stock Sales Agreement with BTIG

The latest update is out from CervoMed ( (CRVO) ). CervoMed Inc. had an agreement in place to sell up to $20 million of its common stock through BTIG, LLC, under a Sales Agreement that allowed for “at-the-market” offerings. However, the company decided to terminate this agreement without incurring any penalties or selling any shares under this arrangement. The termination will take effect on October 11, 2024. For detailed information about CRVO stock, go to TipRanks’ Stock Analysis page.

TipRanks 2 months ago

CRVO
CervoMed to Participate in 3rd Annual ROTH Healthcare Opportunities Conference

Dr. John Alam to Participate in Panel Titled “Opportunities and Challenges When Small Names Go After Blockbuster Indications”BOSTON, Oct. 02, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage company focused on developing treatments for age-related neurologic disorders, today announced that Dr. John Alam, Chief Executive Officer, is scheduled to participate in a panel discussion and one-on-one investor meetings at the 3rd Annual ROTH Healthcare Opportunities Conference, bei

GlobeNewswire 2 months ago

CRVO
CervoMed to Deliver Late-Breaking Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)

Plasma biomarker data from AscenD-LB Phase 2a study and baseline data from the RewinD-LB Phase 2b study to be featured in late-breaking oral presentations at CTADBOSTON, Sept. 26, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage company focused on developing treatments for age-related neurologic disorders, today announced that it will deliver two oral presentations that inform on the potential of neflamapimod as a treatment for patients with dementia with Lewy bodies (DLB)

GlobeNewswire 2 months ago

CRVO
With 35% ownership, insiders at CervoMed Inc. (NASDAQ:CRVO) are pretty optimistic and have been buying recently

Key Insights Significant insider control over CervoMed implies vested interests in company growth 53% of the business...

Simply Wall St. 2 months ago

CRVO
CervoMed Featured in Fortune for Advances in the Treatment of Dementia with Lewy Bodies

BOSTON, Aug. 22, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced its recent feature in Fortune magazine. In the article, titled “A New Hope for Dementia Treatment”, CervoMed was recognized for its pioneering work in developing neflamapimod, a potentially transformative treatment for patients suffering from dementia with Lewy bodies (DLB). “We are honored to be featured in Fortun

GlobeNewswire 3 months ago

CRVO
CervoMed Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

- Completed enrollment in its RewinD-LB Phase 2b clinical trial evaluating neflamapimod in patients with early-stage dementia with Lewy bodies (DLB) in June 2024; topline data expected in December 2024 - - Hosted a virtual key opinion leader event in July 2024 highlighting neflamapimod’s potential for patients with early-stage DLB – - Completed private placement for up to $149.4 million of potential proceeds with leading institutional healthcare investors in April 2024 – - Added to the Russell 2

GlobeNewswire 4 months ago

CRVO
CervoMed Second Quarter 2024 Earnings: Beats Expectations

CervoMed ( NASDAQ:CRVO ) Second Quarter 2024 Results Key Financial Results Revenue: US$3.29m (up 116% from 2Q 2023...

Simply Wall St. 4 months ago

CRVO
Morgan Stanley Predicts up to ~230% Surge for These 2 ‘Strong Buy’ Stocks

The S&P 500 plunged on Friday after a weak jobs report intensified concerns that the Federal Reserve’s decision to maintain rates at a two-decade high could lead to a deeper economic slowdown. Nevertheless, conventional wisdom anticipates that the Fed will begin cutting rates in September. In fact, Fed-funds futures now suggest a 71.5% probability of a double rate cut (50 basis points) at the Federal Open Market Committee’s September meeting. This marks a significant increase from the 22% probab

TipRanks 4 months ago

CRVO

Performance Overview

Return	DP8.SG	S&P 500
YTD	-65.71%	+26.86%
1-Year	-65.71%	+30.31%
3-Year	-92.69%	+28.42%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

CervoMed Inc. (DP8.SG)

CervoMed price target lowered to $4 from $45 at Roth MKM

CervoMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CervoMed announces RewinD-LB Phase 2b did not meet primary endpoint

CervoMed Announces Topline Data from RewinD-LB Phase 2b Clinical Trial in Patients with Dementia with Lewy Bodies

CervoMed Announces Orphan Drug Designation Granted to Neflamapimod by U.S. Food and Drug Administration for the Treatment of Frontotemporal Dementia

CervoMed Announces Key Senior Leadership Appointments

CervoMed Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

CervoMed Awarded the Prix Galien USA 2024 Prize for Best Startup

CervoMed to Participate in Upcoming Investor Conferences

CervoMed Announces Key Takeaways from Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)

CervoMed to Deliver Oral Presentation at the 8th International Lewy Body Dementia Conference

CervoMed Announces Last Patient Last Visit in Phase 2b RewinD-LB Trial of Neflamapimod for the Treatment of Early-Stage Dementia with Lewy Bodies (DLB)

CervoMed Ends $20 Million Stock Sales Agreement with BTIG

CervoMed to Participate in 3rd Annual ROTH Healthcare Opportunities Conference

CervoMed to Deliver Late-Breaking Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)

With 35% ownership, insiders at CervoMed Inc. (NASDAQ:CRVO) are pretty optimistic and have been buying recently

CervoMed Featured in Fortune for Advances in the Treatment of Dementia with Lewy Bodies

CervoMed Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

CervoMed Second Quarter 2024 Earnings: Beats Expectations

Morgan Stanley Predicts up to ~230% Surge for These 2 ‘Strong Buy’ Stocks

Performance Overview